Drugs / glial cell line-derived neurotrophic factor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03652363 | Oct 2012 → Mar 2015 | Parkinson disease | North Bristol NHS Trust | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glial cell line-derived neurotrophic factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03652363 ↗ |
| Known as | Hgdnf expressed protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068580 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant-methionyl human glial cell line-derived neurotrophic factor” NCT03652363 ↗ |
| Route | Other | “Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery” NCT03652363 ↗ |